+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

New oral anticoagulants for the treatment ofA venous thromboembolism



New oral anticoagulants for the treatment ofA venous thromboembolism







New oral anticoagulants, acting either as direct factor-Xa or thrombin inhibitors, have been evaluated for the acute and long-term treatment of venous thromboembolism (VTE). Dabigatran and rivaroxaban are as effective as conventional therapy (heparin/vitamin K antagonists) without safety concerns. Rivaroxaban allows a single-drug regimen even in patients with pulmonary embolism, while dabigatran requires 5a 7 days of initial heparin treatment. The results of clinical trials with apixaban and edoxaban will become available in the coming months. Rivaroxaban, apixaban and dabigatran are more effective than placebo for the extended treatment of VTE. Apixaban is effective in both therapeutic and prophylactic doses. Considering both efficacy and bleeding complications, all these agents have a favorable net clinical benefit. Dabigatran is as effective and safe as warfarin for the extended treatment of VTE. It is conceivable that the new oral anticoagulants will become the standard therapy for VTE in the next years.

(PDF emailed within 1 workday: $29.90)

Accession: 037114432

Download citation: RISBibTeXText


Related references

New oral anticoagulants for the treatment of venous thromboembolism. Best Practice & Research. Clinical Haematology 26(2): 151-161, 2014

Oral anticoagulants for the treatment of venous thromboembolism. Bailliere's Clinical Haematology 11(3): 639-661, 1999

New oral anticoagulants in the treatment of venous thromboembolism. Presse Medicale 42(9 Pt 1): 1232-1238, 2013

New oral anticoagulants for treatment of venous thromboembolism. Deutsche Medizinische Wochenschrift 136(22): 1162-1164, 2011

Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 20(5): 490-500, 2016

Management of oral anticoagulants in the treatment of venous thromboembolism. European Journal of Internal Medicine 12(2): 75-85, 2001

Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 124(7): 1020-1028, 2015

Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. Hematology/Oncology Clinics of North America 30(5): 1035-1051, 2016

The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants. Expert Opinion on PharmacoTherapy 16(16): 2391-2394, 2016

Direct oral anticoagulants for venous thromboembolism treatment and prophylaxis. Jaapa 29(8): 24-29, 2016

Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. Seminars in Thrombosis and Hemostasis 41(2): 160-165, 2015

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. Blood Research 49(2): 77-79, 2014

The place of novel oral anticoagulants in prevention and treatment of venous thromboembolism. Angiologiia i Sosudistaia Khirurgiia 20(3): 89-93, 2014

Prevention and treatment of venous thromboembolism: the place of new oral anticoagulants. Revista Portuguesa de Cardiologia 31 Suppl 1: 45-50, 2014

Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology 35(3): 513-519, 2016